157327-43-0

Basic information

• Product Name: TERT-BUTYL 3-ACETYL-4-OXOPIPERIDINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 3-ACETYL-4-OXOPIPERIDINE-1-CARBOXYLATE;1-Piperidinecarboxylic acid, 3-acetyl-4-oxo-, 1,1-dimethylethyl ester
• CAS NO: 157327-43-0
• Molecular Formula: C₁₂H₁₉NO₄
• Molecular Weight: 241.29
• Mol File: 157327-43-0.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 355.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.135±0.06 g/cm3(Predicted)
• PKA: 9.93±0.20(Predicted)
• CAS DataBase Reference: TERT-BUTYL 3-ACETYL-4-OXOPIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 3-ACETYL-4-OXOPIPERIDINE-1-CARBOXYLATE(157327-43-0)
• EPA Substance Registry System: TERT-BUTYL 3-ACETYL-4-OXOPIPERIDINE-1-CARBOXYLATE(157327-43-0)

Safety Data

• Hazardous Substances Data: 157327-43-0(Hazardous Substances Data)

Usage

General Description

Tert-Butyl 3-acetyl-4-oxopiperidine-1-carboxylate is a chemical compound consisting of a piperidine ring with tert-butyl, acetyl, and carboxylate functional groups attached. It is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. TERT-BUTYL 3-ACETYL-4-OXOPIPERIDINE-1-CARBOXYLATE has potential applications in medicinal chemistry due to its ability to serve as a building block for the creation of diverse chemical structures. Additionally, its tert-butyl group provides stability and contributes to its favorable properties as a reagent in organic synthesis.

Upstream product

• 34619-03-9 tert-butyldicarbonate 
• 41979-39-9 4-piperidone hydrochloride 
• 123-75-1 pyrrolidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 108-24-7 acetic anhydride 
• 75-36-5 acetyl chloride 
• 207691-65-4 N-tert-butoxycarbonyl-4-(tetrahydropyrrole-1-yl)-1,2,3,6-tetrahydropyridine 
• 762-75-4 tert-butyl formate 
• 141-78-6 ethyl acetate 
• 217807-98-2 4-morpholin-4-yl-3,6-dihydro-2H-pyridine-1-carboxylic acid ter-tbutyl ester 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2466-76-4 N-Acetylimidazole 

Downstream Products

• 1438076-49-3 N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(3-methyl-6,7-dihydroisoxazolo[4,3-c]pyridin-5(4H)-yl)propoxy)quinazolin-4-amine 
• 733757-77-2 tert-butyl 3-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxylate 
• 1449478-41-4 C₁₄H₁₅BrN₄O 
• 1449478-42-5 C₁₄H₁₅ClN₄O 
• 1449478-43-6 C₁₅H₁₅F₃N₄O 
• 1449478-44-7 C₁₆H₂₀N₄O 
• 1449478-45-8 C₁₆H₂₀N₄O 
• 1449478-46-9 C₁₆H₂₀N₄O 
• 1449478-47-0 C₁₄H₁₄F₂N₄O 
• 1449478-48-1 C₁₅H₁₇FN₄O 
• 1449478-57-2 N-(4-bromophenyl)-5-ethyl-3-methyl-4,5,6,7-tetrahydro-1Hpyrazolo[4,3-c]pyridine-1-carboxamide 
• 1449478-64-1 N-(4-chlorophenyl)-5-ethyl-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-1-carboxamide 
• 1449478-63-0 5-ethyl-3-methyl-N-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-1-carboxamide 
• 1449478-60-7 N-(2,4-dimethylphenyl)-5-ethyl-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-1-carboxamide 

Relevant articles and documents

Pyrazolyl-pyrimidones inhibit the function of human solute carrier protein SLC11A2 (hDMT1) by metal chelation

Solute carrier proteins (SLCs) control fluxes of ions and molecules across biological membranes and represent an emerging class of drug targets. SLC11A2 (hDMT1) mediates intestinal iron uptake and its inhibition might be used to treat iron overload diseases such as hereditary hemochromatosis. Here we report a micromolar (IC50 = 1.1 μM) pyrazolyl-pyrimidone inhibitor of radiolabeled iron uptake in hDMT1 overexpressing HEK293 cells acting by a non-competitive mechanism, which however does not affect the electrophysiological properties of the transporter. Isothermal titration calorimetry, competition with calcein, induced precipitation of radioactive iron and cross inhibition of the unrelated iron transporter SLC39A8 (hZIP8) indicate that inhibition is mediated by metal chelation. Mapping the chemical space of thousands of pyrazolo-pyrimidones and similar 2,2′-diazabiaryls in ChEMBL suggests that their reported activities might partly reflect metal chelation. Such metal chelating groups are not listed in pan-assay interference compounds (PAINS) but should be checked when addressing SLCs.

NEW ANTIBACTERIAL COMPOUNDS

The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.

EZH2 INHIBITORS AND USES THEREOF

The present invention provides compound of formula 1, or an isotopic form, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, S-oxide or N-oxide thereof. The invention also relates toprocesses for their preparation, to pharmaceutical compositions containing them and use of the compound of formula 1, in the treatment of diseases or disorders mediated by EZH2 (enhancer of zeste homolog 2), particularly cancer.